or
Remember me
Back
Algernon Pharmaceuticals (AGN.c AGNPF) CEO on the company's Phase 1 DMT Clinical Stroke Study, why the company decided to create a subsidiary for its DMT research (Algernon Nuro) and plans to raise money for the subsidiary.
Receive investor kits and email updates from Stockhouse and directly from these companies.